[
  {
    "ts": null,
    "headline": "Does This Move Make Merck Stock a Buy?",
    "summary": "Merck is seeking ways to prepare for a significant upcoming patent cliff.  The company has just announced another acquisition that will help it achieve that goal.  With its newer products, strong dividend, and reasonable valuation, Merck still looks attractive.",
    "url": "https://finnhub.io/api/news?id=3a2dcbacdb0c1a4b4b2ca6c89e07fa73501eebb0b035e0fffabbb9e918f9d2c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753019400,
      "headline": "Does This Move Make Merck Stock a Buy?",
      "id": 136019805,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is seeking ways to prepare for a significant upcoming patent cliff.  The company has just announced another acquisition that will help it achieve that goal.  With its newer products, strong dividend, and reasonable valuation, Merck still looks attractive.",
      "url": "https://finnhub.io/api/news?id=3a2dcbacdb0c1a4b4b2ca6c89e07fa73501eebb0b035e0fffabbb9e918f9d2c8"
    }
  },
  {
    "ts": null,
    "headline": "Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?",
    "summary": "One of the big reasons to like Pfizer (NYSE: PFE) today is its huge 7.1% dividend yield.  Pfizer competitor Merck (NYSE: MRK) is yielding a little more than 4%, yet dividend investors will probably be better off with Merck.  While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today.",
    "url": "https://finnhub.io/api/news?id=bca9fdd5f357334c8451771fae1f2bde7504420aa9c381827b0f7339ac532ca2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753017900,
      "headline": "Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?",
      "id": 136019806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "One of the big reasons to like Pfizer (NYSE: PFE) today is its huge 7.1% dividend yield.  Pfizer competitor Merck (NYSE: MRK) is yielding a little more than 4%, yet dividend investors will probably be better off with Merck.  While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today.",
      "url": "https://finnhub.io/api/news?id=bca9fdd5f357334c8451771fae1f2bde7504420aa9c381827b0f7339ac532ca2"
    }
  }
]